3 years ago

Optellum Raises €14 Million to Advance AI-Powered Lung Cancer Detection

  • Optellum, a UK-based medtech startup developing AI-powered lung cancer detection software, has secured €14 million in Series A funding led by Mercia

  • The funding will be used to accelerate the development of Optellum's technology and expand internationally

  • The company's platform helps physicians identify and track at-risk patients, enabling early diagnosis and treatment of lung cancer

  • Optellum has achieved FDA 510(k) clearance and is being used in the UK in a multi-center study with NHS Trusts

  • The investment round also included participation from Intuitive Ventures, Black Opal Ventures, St John’s College, IQ Capital, and the family office of Sir Martin and Lady Audrey Wood.

      • ProblemHealthcare

      "Lung cancer is the leading cause of cancer deaths worldwide, and early diagnosis is crucial for improving patient outcomes. Current diagnosis methods often lead to late detection, resulting in a low five-year survival rate. "

      Solution

      "Optellum has developed an AI-based decision-support software that helps physicians identify and track at-risk patients, enabling early diagnosis of lung cancer. This allows for earlier treatment and potentially improves survival rates. The software also helps minimize invasive procedures like biopsies on benign lesions."

      Covered on